
    
      A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study
      to Evaluate Corticosteroid-reduction and -sparing effects of Mepolizumab 750 mg intravenously
      in Subjects with Hypereosinophilic Syndromes (HES) and to evaluate the Efficacy and Safety of
      Mepolizumab in controlling the Clinical Signs and Symptoms of HES over Nine Months
    
  